Personalized clinical managements through exploring circulating neural cells and electroencephalography

Table 1 Erythroblastosis virus E26 oncogene homolog 2 protein expressions status and clinical features of Alzheimer's disease patients

Case No	Gender	Age, yr	Clinical feature	Family History of AD (years old)	Ets2 protein expression (%)	Total cells evaluated by flow-cytometry
1	F	69	ML	-	146 (3.47)	4207
2	F	57	ML, tremble (hands)	Cousin of paternal father (65)	155 (2.13)	7276
3	F	92	ML, MD	-	121 (1.11)	10900
4	M	76	ML	Half brother (70)	607 (15.8)	3841
5	M	79	ML	-	810 (11)	7363
6	M	67	ML (severe)	-	166 (2.43)	6831
7	M	42	ML (severe)	-	1100 (6.75)	16296
8	F	54	ML	-	228 (3)	7600
9	F	81	ML, HC, BP	Maternal aunt (95)	98 (5.12)	1914
10	F	79	ML	-	541 (18.9)	2862

M: Male; F: Female; ML: Memorial loss; MD: Movement disorder; HC: Heart complication, BP: High blood pressure; AD: Alzheimer disease; Ets2: Erythroblastosis virus E26 oncogene homolog 2; Total cells analyzed in 10 patients: 69090[11].

Table 2 Erythroblastosis virus E26 oncogene homolog 2 protein expressions status in healthy individuals as control for the patients with Alzheimer disease

ID	Age, yr	Ets2 protein expression (%)	Total cells analyzed
C-1	65	2 (0.066)	3025
C-2	56	10 (0.19)	5214
C-3	79	0 (0)	1546
C-4	74	3 (0.065)	4587
C-5	79	6 (0.48)	1232
C-6	62	3 (0.38)	783
C-7	42	0 (0)	923
C-8	54	4 (0.10)	9823
C-9	81	7 (004)	874
C-10	79	3 (0.19)	1542
Total		38 (0.12)	29549

The cells were analysed by flow cytometry: All controls (C) had no family history of Alzheimer disease. C: Control; Ets2: Erythroblastosis virus E26 oncogene homolog 2.